Oncopeptides AB (publ) (OM: ONCO)
Health Care · Biotechnology · SE
Skr2.96
+40.74% today · -46.6% 1Y
Oncopeptides AB (publ) (OM: ONCO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $117.17M and employs 69 people.
Over the last twelve months the share price has lost 46.6%, trading between 1.26 and 6.14.
Tweenvest scores Oncopeptides AB (publ) across four factors: quality 30/100, value 73/100. Its strongest factor is value.
ONCO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $117.17M
- Revenue (TTM)
- $9.82M
- P/E
- —
- EPS
- -0.76
- Dividend yield
- —
- Beta (5Y)
- -1.42
- 52-week high
- Skr6.14
- 52-week low
- Skr1.26
- Avg volume (3M)
- —
- Shares outstanding
- 395.29M
- Employees
- 69
- Next earnings
- —
About Oncopeptides AB (publ)
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
- ISIN
- SE0009414576
- Founded
- 2000
- Listed since
- Feb 22, 2017
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Anterogen.Co.,Ltd.KOSDAQ: A065660 | $120.50M | ₩16,190.00 | +7.65% |
| Foghorn Therapeutics Inc.NasdaqGM: FHTX | $118.77M | $1.90 | -5.00% |
| Cibus, Inc.NasdaqCM: CBUS | $118.46M | $1.42 | -8.71% |
| Nykode Therapeutics ASOB: NYKD | $117.42M | Nkr3.20 | -6.98% |
| Heidelberg Pharma AGXTRA: HPHA | $116.82M | €2.23 | -5.11% |
| Coya Therapeutics, Inc.NasdaqCM: COYA | $116.12M | $4.60 | -7.07% |
| enGene Therapeutics Inc.NasdaqCM: ENGN | $115.94M | $1.63 | -6.07% |
| 4basebio PLCAIM: 4BB | $115.66M | £5.63 | 0.00% |
Figures last refreshed Oct 11, 2026.